Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEM 1003 in mild to moderate Alzheimer's disease
NCT00257673Phase 2Completed
- Sponsor
- Memory Pharmaceuticals
- Start
- Nov 2005
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MEM 1003 in Alzheimer's disease (AD), sponsored by Memory Pharmaceuticals. Started Nov 2005; status: completed.
02
Drugs
MEM 1003
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00257673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257673.